Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cc-401. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 known ✓ | P45983 | 1/20 | 1.00 |
| ▸ | MAPK9 known ✓ | P45984 | 1/20 | 1.00 |
| ▸ | MAPK10 known ✓ | P53779 | 1/20 | 1.00 |
| ▸ | CLK2 | P49760 | 3/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 3/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | NQO2 | P16083 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 1/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cc-401 SCHEMBL30290855 | 1.00 | CLK2 (1.00) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| SCHEMBL8253744 | 1.00 | CLK2 (1.00) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| Cc-401 SCHEMBL29403560 | 0.99 | CLK2 (0.98) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| Cc-401 SCHEMBL30198024 | 0.99 | CLK2 (0.98) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| Cc-401 SCHEMBL29538788 | 0.99 | CLK2 (0.98) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| Cc-401 SCHEMBL23924447 | 0.99 | CLK2 (0.98) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| Cc-401 SCHEMBL29249167 | 0.99 | CLK2 (0.98) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| SCHEMBL5373334 | 0.99 | CLK2 (0.98) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| SCHEMBL5375716 | 0.95 | CLK2 (0.91) | CLK2DYRK1AMAP4K4GAKDYRK3 | |
| SCHEMBL5372579 | 0.92 | CLK2 (0.84) | CLK2DYRK1AMAP4K4GAKDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012106702-A2 | TREATMENT OF LEUKEMIA | THE GENERAL HOSPITAL CORPORATION (US) | 2012-08-09 | — | — | WO | claimed |
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-12414981-B2 | JNK inhibitors for use in treating and preventing neurodegenerative disorders | NORTHWESTERN UNIVERSITY (US) | 2025-09-16 | — | — | US | disclosed |
| WO-2025028555-A1 | CASK DISORDER TREATING AGENT AND TREATMENT METHOD | 国立大学法人信州大学 | 2025-02-06 | — | — | WO | disclosed |
| US-20240400983-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240392241-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| WO-2024171957-A1 | TRANSPLANTATION OF PITUITARY HORMONE-PRODUCING CELLS | 国立大学法人東海国立大学機構 | 2024-08-22 | — | — | WO | disclosed |
| EP-4410963-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | Sumitomo Chemical Company, Limited (JP) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410962-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-118318033-A | Cell aggregate comprising pituitary hormone-producing cells and method for producing the same | 住友制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| CN-118043447-A | Method for preparing cell population containing pituitary tissue and cell population | 住友化学株式会社 | 2024-05-14 | — | — | CN | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| WO-2004041191-A2 | METHODS FOR THE TREATMENT, PREVENTION AND MANAGEMENT OF MACULAR DEGENERATION | CELGENE CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040092568-A1 | Methods for the treatment, prevention and management of macular degeneration | CELGENE CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | MAPK8 26/4885MAPK9 41/4885MAPK10 50/4885 |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAPK8 25/4885MAPK9 34/4885MAPK10 65/4885 |
| US-20040092568-A1 | Methods for the treatment, prevention and management of macular degeneration | ALDH1A2, MAPK1, MAPK3 | MAPK8 31/4885MAPK9 78/4885MAPK10 38/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAPK8 25/4885MAPK9 34/4885MAPK10 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.